As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes. To read the full article, click here


Established in 2001 in partnership with St George’s University of London, Richmond Pharmacology’s aim was to create a structure where practising physicians were actively involved in clinical research. Profits were reinvested into the business or used to fund academic research in underfunded areas - leading to the creation of Richmond Research Institute in 2020.


Two decades later and the landscape of early phase clinical research has changed dramatically. Moving from small molecules whose effects were studied for numerous medical conditions to therapeutics such as mRNA, siRNA, and gene editing which treat specific disease pathways. 


This progressive course of education and regulatory environment must continue if we are to align with the advancements in precision medicine. 


Read Dr Taubel’s full reflection in the PharmaTimes.

Latest news

PATIENT WITH RARE BLEEDING DISORDER BECOMES FIRST TO TEST NEW TREATMENT

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event